$ITOR
Intorio, Corp.

2024 Q3 Form 10-Q Financial Statement

#000168316824007515 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q1 2023 Q3
Revenue $0.00 $750.00 $750.00
YoY Change -100.0% -53.13%
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $750.00
YoY Change -100.0%
Gross Profit Margin 100.0%
Selling, General & Admin $12.94K $12.11K $4.330K
YoY Change 198.94% 131.99% -27.1%
% of Gross Profit 577.33%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $670.00 $660.00
YoY Change 0.0% -50.38%
% of Gross Profit 88.0%
Operating Expenses $12.94K $12.11K $4.326K
YoY Change 199.21% 131.99% -27.21%
Operating Profit -$12.94K -$3.576K
YoY Change 261.97% -39.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.94K -$11.36K -$3.580K
YoY Change 261.56% 213.81% -39.76%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.94K -$11.36K -$3.576K
YoY Change 261.97% 213.81% -39.83%
Net Earnings / Revenue -1514.67% -476.8%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.235M shares 3.235M shares 3.235M shares
Diluted Shares Outstanding 3.235M shares 3.235M shares

Balance Sheet

Concept 2024 Q3 2024 Q1 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $920.00 $1.660K
YoY Change -49.17% -58.08%
Cash & Equivalents $0.00 $921.00 $1.661K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $921.00 $1.661K
YoY Change -49.12% -58.04%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $997.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $997.00 $2.331K
YoY Change -72.8% -53.37%
TOTAL ASSETS
Total Short-Term Assets $921.00 $1.661K
Total Long-Term Assets $997.00 $2.331K
Total Assets $0.00 $1.918K $3.992K
YoY Change -100.0% -64.97% -55.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.36K $27.50K $24.50K
YoY Change -57.7% 27.91% 32.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $26.66K $17.95K
YoY Change 196.88% 181.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.16K $42.45K
YoY Change 77.68% 70.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $54.16K $42.45K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $12.94K $54.16K $42.45K
YoY Change -69.51% 77.69% 70.62%
SHAREHOLDERS EQUITY
Retained Earnings -$92.01K -$77.14K -$63.36K
YoY Change 45.21% 54.58% 55.21%
Common Stock $324.00 $324.00 $324.00
YoY Change 0.0% 0.0% 0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.94K -$52.24K -$38.46K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $1.918K $3.992K
YoY Change -100.0% -64.97% -55.44%

Cashflow Statement

Concept 2024 Q3 2024 Q1 2023 Q3
OPERATING ACTIVITIES
Net Income -$12.94K -$11.36K -$3.576K
YoY Change 261.97% 213.81% -39.83%
Depreciation, Depletion And Amortization $670.00 $660.00
YoY Change 0.0% -50.38%
Cash From Operating Activities -$9.190K -$1.410K
YoY Change 533.79% -88.28%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.200K 410.0
YoY Change 228.0% 192.86%
NET CHANGE
Cash From Operating Activities -9.190K -1.410K
Cash From Investing Activities
Cash From Financing Activities 8.200K 410.0
Net Change In Cash -990.0 -1.000K
YoY Change -194.29% -91.59%
FREE CASH FLOW
Cash From Operating Activities -$9.190K -$1.410K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
333-255055
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1578603
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei City Area Code
CityAreaCode
(323)
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Intorio, Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Address Address Line1
EntityAddressAddressLine1
17875 Von Karman Avenue
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92614
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001852536
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-08-31
dei Local Phone Number
LocalPhoneNumber
909-2866
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3235000 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
921 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
997 usd
CY2024Q3 us-gaap Assets
Assets
0 usd
CY2024Q1 us-gaap Assets
Assets
1918 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10364 usd
CY2024Q3 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
2580 usd
CY2024Q1 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
27500 usd
CY2024Q3 NONE Director Loan
DirectorLoan
0 usd
CY2024Q1 NONE Director Loan
DirectorLoan
26661 usd
CY2024Q3 us-gaap Liabilities
Liabilities
12944 usd
CY2024Q1 us-gaap Liabilities
Liabilities
54161 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
324 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
324 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
78737 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24576 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92005 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77143 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12944 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-52243 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1918 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
750 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
2100 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
750 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
2100 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12944 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4326 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13865 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15553 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12944 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3576 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13865 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13453 usd
CY2024Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-997 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12944 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3576 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14862 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13453 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12944 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3576 usd
us-gaap Net Income Loss
NetIncomeLoss
-14862 usd
us-gaap Net Income Loss
NetIncomeLoss
-13453 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3235000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3235000 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12944 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12944 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-52243 usd
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
54160 usd
us-gaap Net Income Loss
NetIncomeLoss
-14862 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-12944 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-34883 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3576 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-38459 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-25006 usd
us-gaap Net Income Loss
NetIncomeLoss
-13453 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-38459 usd
us-gaap Net Income Loss
NetIncomeLoss
-14862 usd
us-gaap Net Income Loss
NetIncomeLoss
-13453 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1334 usd
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-997 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10364 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3501 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9119 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2580 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8970 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2580 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8970 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-921 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-149 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
921 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1810 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1661 usd
NONE Forgiveness Of Loan From Shareholder In Exchange For Contribution
ForgivenessOfLoanFromShareholderInExchangeForContribution
54161 usd
NONE Forgiveness Of Loan From Shareholder In Exchange For Contribution
ForgivenessOfLoanFromShareholderInExchangeForContribution
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92005 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77143 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_z1yq3aSyU6Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results and outcomes may differ from management’s estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to limited level of operations during the reporting period, the Company made no material assumptions or estimates other than the assumption that the Company is going concern and estimate with reference to amortization of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3235000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3235000 shares

Files In Submission

Name View Source Status
0001683168-24-007515-index-headers.html Edgar Link pending
0001683168-24-007515-index.html Edgar Link pending
0001683168-24-007515.txt Edgar Link pending
0001683168-24-007515-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
intorio_ex3101.htm Edgar Link pending
intorio_ex3102.htm Edgar Link pending
intorio_ex3201.htm Edgar Link pending
intorio_i10q-83124.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20240831.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
intorio_i10q-83124_htm.xml Edgar Link completed
none-20240831_cal.xml Edgar Link unprocessable
none-20240831_def.xml Edgar Link unprocessable
none-20240831_pre.xml Edgar Link unprocessable
none-20240831_lab.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending